Three firms in EU get nods on pegfilgrastim

Three firms – Mundipharma, Mylan and Sandoz – have received final pan-European marketing authorisations from the European Commission for biosimilar rivals toAmgen’s Neulasta (pegfilgrastim). The nods for Mundipharma’s Pelmeg, Mylan’s Fulphila and Sandoz’ Ziextenzo followed positive recommendations from the European Medicines Agency’s (EMA’s) committee for human medicinal products (CHMP) towards the end of September (Generics bulletin, 28 September 2018, page 15).